A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Merck Staphylococcus Aureus Vaccine (V710) in Adult Patients With End-Stage Renal Disease on Chronic Hemodialysis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Merck Staphylococcus Aureus Vaccine (V710) in Adult Patients With End-Stage Renal Disease on Chronic Hemodialysis.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2015

At a glance

  • Drugs V-710 (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 19 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Planned end date changed from 1 Mar 2010 to 1 Feb 2010 as reported by ClinicalTrials.gov.
    • 30 Oct 2009 Actual patient number (201) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top